{
  "docId": "019de075-2875-74d4-8194-84b6aaf5cb83",
  "docSlug": "17078b9c485724b1d98591e3cd98aa3e",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 60,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses color-coded text (orange) to emphasize key positive outcomes within the bullet points.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2875-74d4-8194-84b6aaf5cb83/33",
  "deckHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83",
  "deckJsonHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83.json",
  "deckAnchorHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.91,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "list",
      "text": "KT-474 administered to HS and AD patients at 75 mg QD for 28 days shown to have safety, PK and PD comparable to healthy volunteers\nModest, non-adverse QTcF prolongation observed to spontaneously resolve back to baseline during final 2 weeks of dosing in HS and AD patients\nRobust degradation of IRAK4 in blood and skin was associated with systemic anti-inflammatory effect in HS and AD patients\nPromising clinical activity observed in HS and AD exceeding benchmark placebo rates and comparing favorably to SOC biologics\nData presented here validate IRAK4 degradation as a potential best in class mechanism in inflammatory diseases and its superior clinical potential over SMI\nResults support advancing KT-474 into Phase 2 placebo-controlled trials, Sanofi has committed to start Ph2 clinical trials initially in HS and AD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9565b98c-d7f3-48ea-bc56-e22868b87b90",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.18,
        "x": 0.41,
        "y": 0.04
      },
      "kind": "title",
      "text": "Part C Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7712bede-253c-4105-a36f-7d034cb7d589",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}